Achmea Investment Management B.V. Purchases 15,083 Shares of Cencora, Inc. (NYSE:COR)

Achmea Investment Management B.V. lifted its position in shares of Cencora, Inc. (NYSE:COR) by 16.3% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 107,359 shares of the company’s stock after buying an additional 15,083 shares during the quarter. Achmea Investment Management B.V. owned about 0.05% of Cencora worth $24,188,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Financial Advocates Investment Management raised its stake in Cencora by 4.7% in the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock worth $220,000 after purchasing an additional 44 shares in the last quarter. Checchi Capital Advisers LLC raised its position in shares of Cencora by 2.2% in the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock valued at $499,000 after buying an additional 48 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in shares of Cencora by 3.4% in the second quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company’s stock valued at $353,000 after buying an additional 51 shares during the period. Barlow Wealth Partners Inc. grew its position in Cencora by 5.4% during the second quarter. Barlow Wealth Partners Inc. now owns 1,339 shares of the company’s stock worth $303,000 after buying an additional 68 shares in the last quarter. Finally, Tevis Investment Management increased its stake in Cencora by 4.9% during the 2nd quarter. Tevis Investment Management now owns 1,476 shares of the company’s stock worth $333,000 after acquiring an additional 69 shares during the period. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on COR shares. Leerink Partners reissued an “outperform” rating and set a $275.00 target price on shares of Cencora in a report on Thursday, June 27th. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Robert W. Baird dropped their target price on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research report on Friday, September 6th. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Wells Fargo & Company lifted their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Cencora has an average rating of “Moderate Buy” and a consensus price target of $258.13.

Cencora Stock Performance

Shares of Cencora stock opened at $236.22 on Thursday. The company’s 50 day moving average price is $233.00 and its two-hundred day moving average price is $233.22. The firm has a market capitalization of $47.11 billion, a P/E ratio of 25.84, a P/E/G ratio of 1.54 and a beta of 0.44. Cencora, Inc. has a fifty-two week low of $172.41 and a fifty-two week high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $74.20 billion for the quarter, compared to the consensus estimate of $73.32 billion. During the same quarter last year, the business posted $2.92 EPS. Cencora’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, equities analysts forecast that Cencora, Inc. will post 13.61 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a $0.51 dividend. This represents a $2.04 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Friday, August 9th. Cencora’s dividend payout ratio is currently 22.32%.

Insider Activity at Cencora

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at approximately $63,323,746.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the transaction, the chief executive officer now owns 285,088 shares in the company, valued at $63,323,746.56. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The disclosure for this sale can be found here. Insiders sold a total of 4,450,399 shares of company stock worth $1,070,392,799 in the last quarter. 15.80% of the stock is owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.